AU Patent

AU2019228575A1 — Proton pump inhibitors and methods of use in chemoradiation-induced tissue inflammation and scarring

Assigned to Baylor College of Medicine · Expires 2020-09-17 · 6y expired

What this patent protects

Embodiments of the disclosure include methods and compositions related to treatment or prevention of cancer therapy-induced tissue inflammation, dermatitis, and/or scarring. In particular embodiments one or more proton pump inhibitors are provided to an individual before, during,…

USPTO Abstract

Embodiments of the disclosure include methods and compositions related to treatment or prevention of cancer therapy-induced tissue inflammation, dermatitis, and/or scarring. In particular embodiments one or more proton pump inhibitors are provided to an individual before, during, and/or after receiving anticancer therapy. In some embodiments one or more proton pump inhibitors are provided to an individual before, during, and/or after having a health conditions, allergies, genetic factors and/or exposure to one or more irritants.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019228575A1
Jurisdiction
AU
Classification
—
Expires
2020-09-17
Drug substance claim
No
Drug product claim
No
Assignee
Baylor College of Medicine
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.